Manufacturing
The Paris-headquartered giant has put the spotlight on its extensive investments at home.
The CEOs of two early-stage biotechs explain to Scrip why investor interest in ocular gene therapies is surging and how they aim to attract big pharma partners.
CRDMOs, CDMOs and GCCs are driving partnering and invigorating the wider ecosystem as India moves up the innovation value chain. CRDMOs are moving well beyond traditional outsourcing roles, a new report shows.
As pressure mounts to cut costs, reduce environmental impact, and accelerate development, pharmaceutical innovators are rethinking how medicines are made. A new generation of technologies—flow chemistry, biocatalysis, high-throughput experimentation (HTE), and advanced automation—is reshaping the fu
Deal Snapshot: Eli Lilly has become increasingly interested in genetic treatments for the eye and has secured the rights to a high-profile gene therapy for a rare form of childhood blindness.
The drugmaker announced it would work with the tech giant to deploy a supercomputer that it will use to train AI models and enhance drug discovery, development and manufacturing.
Dr. Reddy's doesn’t fully rule out "queries" from the Canadian regulator for generic semaglutide, though it is confident of selling “all its capacity” for the GLP-1 across target markets. A backup CMO site in the US for abatacept is expected to mitigate risks amid tariff and other uncertainties.
Hear experts Matthieu Culié and Alessandro Agosti as they discuss how Olon stands out in a competitive landscape through its fully integrated end-to-end ADC manufacturing expertise, global operations, impurity control and strategic facilities.
The US FDA’s 'Official Action Indicated' tag on Novo Nordisk’s Catalent Indiana plant has led analysts to push their approval timelines for pending applications by Regeneron and Scholar Rock.
Lupin’s plan for a manufacturing unit in the US follows Trump’s threat of tariffs on branded or patented drugs unless a company is “building” a plant in the US. Will similar investments from Indian firms follow?
After tough negotiations which won the country a lower US levy on pharmaceuticals, there still appears to be some confusion within the Japanese government following President Trump's latest announcement on global pharma tariffs.
Leaders from Eli Lilly, Novo Nordisk, Biocon, Dr Reddy’s and Levim discuss the huge India market potential for GLP-1s. Executives from the Indian firms also outlined efforts to build supply chain stability and cost-efficiency for products like semaglutide.
Doors open at £150m vaccine facility which forms part of a £1bn investment in the country on the part of Moderna, as other firms head for the exit.
The UK-headquartered company is investing heavily in the US, with CEO Emma Walmsley among business leaders greeting President Trump on his state visit to the country.
Leaders from Sanofi, AbbVie and Amgen aligned with Trump’s agenda at the Morgan Stanley healthcare conference, but also continued to push for ‘structural’ US market reforms.
As US-India ties rupture, what could it mean for joint calls by the two nations to de-risk the pharma supply chain and could New Delhi consider non-tariff tools to make a point?
OneSource Specialty CEO Neeraj Sharma discusses with Scrip exploratory talks with next-gen GLP-1 innovators, prospects for semaglutide generics and investment in Swedish firm Xbrane, among other topics.
50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis
Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.
A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.